To the top

Page Manager: Webmaster
Last update: 9/11/2012 3:13 PM

Tell a friend about this page
Print version

Development of ELISAs mea… - University of Gothenburg, Sweden Till startsida
Sitemap
To content Read more about how we use cookies on gu.se

Development of ELISAs measuring the extent of TAFI activation.

Journal article
Authors Erik Ceresa
Els Brouwers
Miet Peeters
Christina Jern
Paul J Declerck
Ann Gils
Published in Arteriosclerosis, thrombosis, and vascular biology
Volume 26
Issue 2
Pages 423-8
ISSN 1524-4636
Publication year 2006
Published at Institute of Neuroscience and Physiology, Department of Clinical Neuroscience and Rehabilitation
Pages 423-8
Language en
Links dx.doi.org/10.1161/01.ATV.000019924...
Keywords Biological Markers, Carboxypeptidase U, analysis, blood, Enzyme Activation, Enzyme-Linked Immunosorbent Assay, methods, Humans, Hyperlipidemias, blood, enzymology, Isoenzymes, analysis, blood, Peptide Fragments, analysis, blood, Sensitivity and Specificity, Sweden, Thrombosis, blood, enzymology
Subject categories Medical and Health Sciences

Abstract

OBJECTIVE: To date, quantitation of TAFI antigen levels has been mainly focused on "total" antigen levels and has been shown to yield ambiguous results because of the existence of different isoforms and various degrees of activation. Our objective was to develop assays that allow measuring the extent of TAFI activation. METHODS AND RESULTS: A variety of enzyme-linked immunosorbent assays (ELISAs) were evaluated for their preferential reactivity toward TAFI before and after activation, and toward the recombinantly expressed activation peptide. Three ELISAs with distinct reactivities were selected: recognizing either exclusively nonactivated TAFI, the released activation peptide, or exclusively TAFIa (activated TAFI). Evaluation of TAFI activation during clot lysis revealed that decreases of TAFI levels are associated with increases of the released activation peptide and TAFIa levels. In addition, antigenic measurement of TAFIa parallels activity measured by chromogenic assay. Analyzing plasma samples revealed that subjects with hyperlipidemia had significantly higher plasma levels of both the activation peptide (109.2 versus 95.5; P<0.001) and TAFIa (112.1 versus 103.3; P=0.03), and not of TAFI antigen (92.5 versus 87.9; P=0.07) (results in % of plasma pooled from normolipidemic subjects). CONCLUSIONS: ELISAs that allow to measure the extent of TAFI activation were developed. These ELISAs constitute more sensitive markers in studies on the relationship between TAFI and cardiovascular diseases.

Page Manager: Webmaster|Last update: 9/11/2012
Share:

The University of Gothenburg uses cookies to provide you with the best possible user experience. By continuing on this website, you approve of our use of cookies.  What are cookies?